Drug intelligence / Profile preview

YL-17424

Development stage: Preclinical
Lead developer: 280Bio
Modality: Small Molecules
Administration: Oral

Overview

YL-17424 is an orally bioavailable small molecule inhibitor developed by 280 Bio that targets multiple KRAS mutations. It exhibits high potency and selectivity against common KRAS mutants, including G12D, G12V, and G12C, as well as KRAS-amplified tumors. The compound is designed to inhibit oncogenic KRAS signaling while maintaining lower activity against wildtype KRAS and other RAS isoforms such as NRAS and HRAS, potentially offering a broader therapeutic window and efficacy across various KRAS-driven cancers.

Other names: KRASmulti

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)KRASG12V (KRAS G12V)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on YL-17424.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YL-17424.

Explore the full profile